Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a single-center, open label study to identify adherence levels of commonly prescribed
FDA-approved antiretroviral agents by tracking the decline of drug concentrations in plasma,
urine and saliva following abrupt drug cessation in HIV-negative adults. Results from this
study may provide support for development of a point of care urine testing device to monitor
drug adherence.
Phase:
Early Phase 1
Details
Lead Sponsor:
Rhonda Brand
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)